Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne is well positioned as a strategic life sciences supplier because its best-in-class protein reagents franchise, along with diagnostics and genomics offerings, supports broad demand across pharma, biotech, academic, and diagnostic end markets. Its exposure to emerging biotech and private/SMID biotech makes it highly levered to a funding rebound, while ~15% sales exposure to cell therapy after Wilson Wolf strengthens its relevance to a growing workflow opportunity that large pharma continues to fund. Management is also improving the business mix through the late CY2025 Exosome Diagnostics divestiture and brand consolidation from 10 to 3, which should aid efficiency and margin expansion even as the company remains valued at a premium multiple.

Bio-Techne is facing a difficult fundamental backdrop as life science tools demand has taken years to normalize, with investors still seeing “false starts” in end-market recovery and the downside case already assuming another year of challenged growth and multiple compression. Competitive pressure is rising because key research reagent rivals like PeproTech, Abcam, and BioLegend have been acquired by larger companies with greater resources, heightening share-loss risk across its protein sciences-heavy portfolio. In addition, the company’s ~15% exposure to cell therapy, mixed M&A execution, and potential structural pressure from AI-driven shifts away from wet lab research all weaken the long-term earnings outlook.